- Home
- LVTX
as 02-21-2025 4:00pm EST
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
| Founded: | 2016 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 27.9M | IPO Year: | 2021 |
| Target Price: | $3.33 | AVG Volume (30 days): | 27.7K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $6.47 | Next Earning Date: | 03-19-2025 |
| Revenue: | $7,345,000 | Revenue Growth: | -18.89% |
| Revenue Growth (this year): | 16.68% | Revenue Growth (next year): | N/A |
Latest LAVA Therapeutics N.V. News
LVTX Breaking Stock News: Dive into LVTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
GlobeNewswire
2 months ago
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
GlobeNewswire
6 months ago
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
6 months ago
LAVA Reports Second Quarter 2024 Financial Results and Business Update
GlobeNewswire
8 months ago
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
GlobeNewswire
8 months ago
LAVA Announces Annual Meeting of Shareholders
GlobeNewswire
9 months ago
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
9 months ago
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
Compare LVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LVTX LAVA Therapeutics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.